{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:48:55Z","timestamp":1792464535414,"version":"4.5.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:p>This Viewpoint discusses direct-to-consumer biomarker tests for Alzheimer disease and their implications on future insurance coverage.<\/jats:p>","DOI":"10.1001\/jamaneurol.2023.4811","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T16:00:47Z","timestamp":1702915247000},"page":"107","source":"Crossref","is-referenced-by-count":10,"title":["Direct to Consumer Biomarker Testing for Alzheimer Disease\u2014Are We Ready for the Insurance Consequences?"],"prefix":"10.1001","volume":"81","author":[{"given":"Jalayne J.","family":"Arias","sequence":"first","affiliation":[{"name":"Department of Health Policy and Behavioral Sciences, School of Public Health, Georgia State University, Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Manchester","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Behavioral Sciences, School of Public Health, Georgia State University, Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lah","sequence":"additional","affiliation":[{"name":"Department of Neurology, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"nvp230018r2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1212\/WNL.0000000000000153","article-title":"Confidentiality in preclinical Alzheimer disease studies: when research and medical records meet.","volume":"82","author":"Arias","year":"2014","journal-title":"Neurology"},{"issue":"19","key":"nvp230018r3","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1001\/jama.2019.3384","article-title":"Direct-to-consumer genetic testing and potential loopholes in protecting consumer privacy and nondiscrimination.","volume":"321","author":"Hendricks-Sturrup","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"nvp230018r4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jalz.2014.03.003","article-title":"The clinical use of cerebrospinal fluid biomarker testing for Alzheimer\u2019s disease diagnosis: a consensus paper from the Alzheimer\u2019s Biomarkers Standardization Initiative.","volume":"10","author":"Molinuevo","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"7","key":"nvp230018r5","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archneur.55.7.964","article-title":"Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study.","volume":"55","author":"Slooter","year":"1998","journal-title":"Arch Neurol"},{"issue":"11","key":"nvp230018r6","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/acn3.v7.11","article-title":"Amyloid-\u00df PET and CSF in an autopsy-confirmed cohort.","volume":"7","author":"Reimand","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"nvp230018r7","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1748-720X.2012.00696.x","article-title":"When does an illness begin: genetic discrimination and disease manifestation.","volume":"40","author":"Prince","year":"2012","journal-title":"J Law Med Ethics"},{"issue":"2","key":"nvp230018r8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1377\/hlthaff.24.2.483","article-title":"Genetic testing for Alzheimer\u2019s disease and its impact on insurance purchasing behavior.","volume":"24","author":"Zick","year":"2005","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"nvp230018r9","first-page":"52","article-title":"The last hope: how starting over could save private long-term care insurance.","volume":"29","author":"Arias","year":"2019","journal-title":"Health Matrix"},{"key":"nvp230018r10","first-page":"255","article-title":"Tantamount to fraud: exploring non-disclosure of genetic information in life insurance applications as grounds for policy rescission.","volume":"26","author":"Prince","year":"2016","journal-title":"Health Matrix Clevel"},{"key":"nvp230018r1","unstructured":"ALZFORUM. Direct-to-consumer Alzheimer\u2019s blood test opens Pandora\u2019s box. Accessed November 8, 2023. https:\/\/www.alzforum.org\/news\/community-news\/direct-consumer-alzheimers-blood-test-opens-pandoras-box#comments"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2812950\/jamaneurology_arias_2023_vp_230018_1707344371.93946.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T16:02:18Z","timestamp":1707753738000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2812950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2023.4811","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}